Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
AUTL Stock Chart & Stats
$1.63
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.63
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.11 - $2.70
Previous CloseN/A
Volume359.61K
Average Volume (3M)1.52M
Market Cap
$433.81M
Enterprise Value$413.52M
Total Cash (Recent Filing)$367.41M
Total Debt (Recent Filing)$65.83M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Mar 10, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding266,143,280
10 Day Avg. Volume1,873,833
30 Day Avg. Volume1,518,602
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.40
Price to Sales (P/S)59.25
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue8.09
Enterprise Value/Gross Profit-2.61
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
$8.00Price Target Upside390.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$135.99M
Bulls Say, Bears Say
Bulls Say
Clinical Data And Label ExpansionPhase Ib CATULUS reported a 96% response rate in pediatric relapsed/refractory B‑ALL, supporting progression to Phase II and de‑risking potential label expansion into pediatric oncology indications.
Commercial Operations And Unit EconomicsAn established commercial footprint, a strong initial launch, and management guidance that product sales will support ongoing operations support plans to optimize manufacturing and improve gross margins as more treatment centers onboard.
Safety Profile DifferentiatorReal‑world and academic analyses indicate Aucatzyl/obe‑cel has materially lower rates of cytokine release syndrome and neurotoxic events versus a competing CD19 CAR‑T, supporting broader use in older patients and chronic autoimmune indications with higher safety standards.
Bears Say
Guidance And Sales ForecastsCompany guidance came in meaningfully below analyst and consensus expectations, prompting downward revisions to sales forecasts and increasing uncertainty around near‑term revenue performance.
Reimbursement And Patient StartsA reimbursement coding change that temporarily slowed patient starts has raised concerns about flat revenue growth and weakened near‑term demand momentum.
Valuation And Analyst SentimentSofter guidance and weaker revenue prospects led analysts to cut price targets and contributed to the stock trading close to cash value, creating valuation downside risk.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $1.10 and its highest was $2.70 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Autolus Therapeutics Plc’s market cap is $433.81M.
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is Mar 10, 2026 which is in 5 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Nov 12, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.086.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -0.26.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,143,280 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went down -9.333%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (390.80% Upside)
$8.00 (390.80% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 147.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 11.8%
Last 30 Days ▲ 11.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.92%
12-Months-Change
Fundamentals
Return on Equity
-60.52%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While the company has seen a successful launch of Obe-cel in the U.S. with significant market penetration and expansion into new clinical areas, financial challenges such as high cost of sales and increased operational losses present notable challenges. However, the company is well-capitalized to continue its growth and expansion strategies.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$8.00
▲(390.80% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
0.48% Mutual Funds
10.91% Other Institutional Investors
87.97% Public Companies and Individual Investors